Table 4.
Overall survival analysis and landmark analysis.
| Patients’ Features | Dead (%) | 3-Year OS (%) | Median OS (%) |
p (univ.) | p (multiv.) | |
|---|---|---|---|---|---|---|
| OVERALL | 63 (42.3) | 58.6 | NR | - | - | |
| Age | <45 years | 17 (32.7) | 65.4 | NR | 0.086 | - |
| >45 years | 46 (47.4) | 55.2 | 65 | |||
| Sex | Male | 41 (48.8) | 53.8 | 44 | 0.108 | - |
| Female | 22 (33.8) | 65.0 | NR | |||
| Leukocytes | <30,000/μL | 22 (34.4) | 73.2 | NR | 0.034 | 0.569 |
| >30,000/μL | 44 (48.2) | 47.5 | 23 | |||
| NPM1 | Mutated | 43 (35.8) | 63.5 | NR | 0.002 | 0.034 |
| Unmutated | 20 (69.0) | 40.0 | 16 | |||
| FLT3-ITD | Negative | 18 (29.5) | 73.4 | NR | 0.006 | 0.178 |
| Positive | 45 (51.1) | 48.2 | 23 | |||
| Karyotype | Intermediate | 54 (40.6) | 59.1 | NR | 0.550 | - |
| Unfavorable | 9 (56.2) | 55.6 | 44 | |||
| ELN 1 2017 | Low Risk | 14 (25.0) | 77.0 | NR | 0.000 | 0.048 |
| Intermediate Risk | 19 (37.3) | 58.5 | NR | |||
| High Risk | 30 (71.4) | 35.2 | 13 | |||
| NPM1/FLT3-ITD | NPM1 mut/FLT3-ITD neg | 18 (29.5) | 73.4 | NR | 0.002 | - |
| NPM1 mut/FLT3-ITD pos | 25 (42.4) | 52.7 | NR | |||
| NPM1 wt/FLT3-ITD pos | 20 (69.0) | 40.0 | 16 | |||
| LANDMARK SURVIVAL ANALYSIS | 45/129 (34.9) | 63.6 | NR | |||
| All patients | HSCT in first CR | 15/35 (42.9) | 58.7 | 81 | 0.348 | - |
| No HSCT in first CR | 30/94 (32.9) | 68.9 | NR | |||
| NPM1 mutated | HSCT in first CR | 8/25 (32) | 62.5 | NR | 0.625 | - |
| No HSCT in first CR | 23/83 (37.7) | 73.5 | NR | |||
| FLT3-ITD | HSCT in first CR | 13/28 (46.4) | 56.7 | 81 | 0.970 | - |
| No HSCT in first CR | 18/44 (40.9) | 55.6 | NR | |||
| ELN 1 2017High Risk | HSCT in first CR | 9/14 (64.3) | 50 | 24 | 0.044 | - |
| No HSCT in first CR | 14/19 (73.7) | 27.1 | 13 | |||
1 ELN = European Leukemia Net.